Cocrystal Pharma Inc (STU:8CC)
€ 1.96 -0.01 (-0.51%) Market Cap: 20.23 Mil Enterprise Value: 9.68 Mil PE Ratio: 0 PB Ratio: 1.68 GF Score: 36/100

Cocrystal Pharma Inc at SRAX Sequire Biotechnology Conference (Virtual) Transcript

Feb 02, 2023 / 04:30PM GMT
Release Date Price: €2.67 (+6.81%)
James Martin
Cocrystal Pharma, Inc. - Interim Co-CEO and CFO

Hello, everyone. I'd like to thank all of you for your interest in Cocrystal. I'd like to thank Sequire for having us here. I'll get started on our presentation.

So Cocrystal, about us. We are a therapeutic company distinguished from a vaccine company in that we cure the disease once a person has it, where vaccines are, in general, more preventative. We have drug candidates which have a clinically validated mechanism of action to cure these diseases. In addition, our program derives itself from a proprietary drug discovery platform, which is based on Nobel-Prize-winning technology, and this technology was industrialized to create Cocrystal.

Some of the investment highlights at Cocrystal include that we target large multi-billion-dollar global markets for both acute and pandemic diseases. As I mentioned, all of our virus antivirals come from our proprietary drug discovery platform. In addition, we have several programs. But the ones highlighted here are our oral influenza, which is a PB2 inhibitor.

We just completed

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot